This Mother Started Lysogene Biotech Company to Help Her Daughter


Karen Aiach is the founder and CEO of Lysogene, a biotech company that specializes in gene therapy treatments for central nervous system diseases.

But Aiach doesn’t have a medical or even scientific background. Instead, she worked as an audit specialist for Arthur Andersen and eventually started her own boutique consultancy back in 2001.

She started the company after her young daughter was diagnosed with Sanfilippo Syndrome A, a rare neurodegenerative disease. Sanfilippo Syndrome A has no known cure and can reduce life expectancy dramatically. She told Forbes:

“We were told our six-month-old child would be mentally impaired, then physically handicapped, then die in her second decade. We went rapidly on the web and looked for information. We downloaded scientific articles related to the disease. Our first surprise was to realize that we were able to understand the contents of scientific publications and navigate into these papers and find the authors. We contacted them and started educating ourselves on science behind this syndrome and the symptoms.”

At first, Aiach and her husband simply connected with scientists to learn more about the disease. After learning of the lack of research being done that specifically relates to Sanfilippo Syndrome A, they decided to fund research through their own nonprofit organization.

Eventually, all of the studies and research began taking the shape of an actual drug development program. So Aiach switched from the nonprofit sector to the for-profit one, founding Lysogene in 2009.

Though the business took shape over several years with some careful business-minded consideration, the crux of it is still a mother’s desire to help her daughter and other kids like her. That unusual business path has raised some eyebrows. But it could some day lead to a cure or better treatment options for people suffering from Sanfilippo Syndrome A and similar diseases.

Aiach said:

“The biggest challenge for me at the beginning was that I was not a scientist or a clinician or gene therapist. I was a mother taking responsibility to build a program and manage it. No one else would have done it so I wasn’t infringing on anyone else’s territory, but even so my being a mother of a patient was strange for some people.”

Image: Lysogene/YouTube 5 Comments ▼

Annie Pilon Annie Pilon is a Senior Staff Writer for Small Business Trends, covering entrepreneur profiles, interviews, feature stories, community news and in-depth, expert-based guides. When she’s not writing she can be found exploring all that her home state of Michigan has to offer.

5 Reactions
  1. Sounds complicated. Did she found this by mistake or she’s an expert in the field? It is bound to make some good money because it is a good technology.

    • It wasn’t exactly an accident. But it seemed to grow over time as she learned more about the research and what they were doing.

  2. How has the business developed?

    • Seems to have grown quite a bit. It started out as just this family partnering with researchers to learn more about the disease. Then it was a foundation that funded research. Then it became its own genetics research and drug development project.